Eli Lilly’s Q3 2026 Zepbound sales face strong upward pressure from sustained volume growth in the GLP-1 class, with Q2 2026 Zepbound revenue reaching $4.93 billion—above the $4.73 billion consensus—and Mounjaro at $9.94 billion. Analysts project Q3 Zepbound sales near $5.2 billion, supported by expanded Medicare Part D access via the $50 monthly Bridge program and recent formulary wins, though offset by rebate pressure and price concessions that trimmed realized prices in the prior quarter. Lilly raised full-year 2026 revenue guidance to $85–87 billion after H1 outperformance, with Q3 results due October 29. New KwikPen dosing and positive combination data with Taltz provide additional tailwinds for prescription trends ahead of the print.